Research comparison
Retatrutide vs. semaglutide
One receptor versus three: semaglutide activates only the GLP-1 receptor, retatrutide the receptors for GIP, GLP-1 and glucagon. The established mono-agonist meets the newest generation of incretin research.
| Property | Retatrutid | Semaglutid |
|---|---|---|
| Profile | Lipidated peptide and triple agonist at the GIP, GLP-1 and glucagon receptors, in clinical development (investigational code LY3437943). | Lipidated GLP-1 analogue with a half-life of about one week; approved as a medicinal substance in several products. |
| Sequence | – | – |
| Length | – | – |
| Formula | – | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molar mass | – | 4,114 g/mol |
| CAS | – | 910463-68-2 |
| Purity (current batch, HPLC) | 99.72 % | – |
| Price per mg from | €3.33 | €4.50 |
In the range
For research and laboratory use only. Not for use in humans or animals. The data summarises literature and lab reports; it is not a recommendation for use.